Skye Bioscience to Participate in Upcoming Investment Conferences

Core Insights - Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and metabolic health disorders [1][2] - The company will participate in two upcoming healthcare conferences, including the Jefferies Global Healthcare Conference and the Sachs European BioPharma Obesity Innovation Forum [1] Company Overview - Skye is developing next-generation molecules that modulate G-protein coupled receptors, aiming for first-in-class therapeutics with clinical and commercial differentiation [2] - The company is conducting a Phase 2 clinical trial for nimacimab, a negative allosteric modulating antibody that inhibits CB1, and is also assessing its combination with a GLP-1R agonist (Wegovy®) [2]